RESUMEN
Genus Bauhinia has been widely used in the treatment of diabetes, malaria, cough, headache, fever, piles, dysentery, flatulence, diarrhoea, ulcer and cardiovascular problems. Among 600 species of this genus, Bauhinia variegata, B. purpurea, B. championii, B. racemosa, and B. forficata are commonly used in the traditional medicine and found to be throughly investigated for their medicinal properties. They possess diverse pharmacological activities such as anti-diabetic, anti-microbial, antioxidant, anti-arthritic, cardioprotective, hepatoprotective, nephroprotective, fibrinolytic, and wound healing properties and most of the biological activities are corelating with traditional knowledge. Phytochemical analysis indicated that steroids, terpenoids, and flavonoids are prominent in the selected species, whereas bauhiniastatins, bauhinoxepins, racemosols, roseosides, and bauhichamines are found unique to the genus. This review aims to decipher active molecules from the aforementioned species of Bauhinia covering comprehensive analysis of phytochemistry, pharmacological activities and traditional uses. The data has been carefully analyzed to find compounds or fractions with a translational value. In most of the cases, the pharmacological activities have been established, however, further studies are needed such as safety evaluations, target identification, bioavailability, metabolite identification, and pharmacokinetic properties. In conclusion, the pharmacological potential of Bauhinia plants show promise with various leads such as insulin-like protein, roseoside, bauhiniastatin, and melibiose binding lectin. However, further investigations are required to address existing gaps and advance them towards product development. This review will lay the groundwork for future research initiatives aimed at fully realizing the therapeutic potential of Bauhinia plants.
Asunto(s)
Bauhinia , Bauhinia/química , Estructura Molecular , Medicina Tradicional , Fitoterapia , Flavonoides , Fitoquímicos/farmacología , Fitoquímicos/análisis , Etnofarmacología , Extractos Vegetales/farmacologíaRESUMEN
We have reported earlier, an orally active insulin-like protein (ILP) from Costus igneus having potent hypoglycemic property in STZ-induced diabetic Swiss mice. The blood glucose level was reduced significantly within two hours after feeding ILP orally in an oral glucose tolerance test. The present study elucidates the mechanism underlying the hypoglycemic action of ILP. Mechanism of action of ILP was studied in differentiated L6 myotubes. 2-NBDG uptake stimulated by ILP was studied in differentiated L6 myotubes under normoglycemic, hyperglycemic and induced insulin resistant conditions. ILP treatment significantly increased 2-NBDG uptake in differentiated L6 myotubes. The levels of insulin signaling molecules IRS-1 and GLUT-4 were assessed in ILP treated L6 myotubes by immunoblot analysis of cytoplasmic and plasma membrane fractions respectively. Immunoblot analysis revealed an increase in cytoplasmic IRS-1 with a concomitant increase in GLUT-4 translocation to the plasma membrane in a time dependent manner. Toxicity studies of ILP were performed on normal as well as diabetic Swiss albino mice. ILP did not show any toxicity in the acute and sub-chronic toxicity studies in normal as well as diabetic Swiss albino mice. Mass spectrometry was carried out to identify ILP. MALDI TOF/TOF MS analysis of ILP revealed sequence homology with the predicted protein from Physcomitrella patens. Our study reveals that ILP acts via insulin signaling pathway and can be used as oral insulin mimetic.